Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis Review uri icon

Overview

MeSH Major

  • Apolipoprotein A-I
  • Cardiovascular Diseases
  • Cholesterol, HDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors

abstract

  • Among patients treated with statin therapy, HDL-C and apoA-I levels were strongly associated with a reduced cardiovascular risk, even among those achieving very low low-density lipoprotein cholesterol. An apoA-I increase was associated with a reduced risk of major cardiovascular events, whereas for HDL-C this was not the case. These findings suggest that therapies that increase apoA-I concentration require further exploration with regard to cardiovascular risk reduction.

publication date

  • October 2013

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC3807966

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.113.002670

PubMed ID

  • 23965489

Additional Document Info

start page

  • 1504

end page

  • 12

volume

  • 128

number

  • 14